ImmuCell Co. Short Interest Update

ICCC Stock  USD 3.69  0.03  0.82%   
About 52% of ImmuCell's investor base is interested to short. The analysis of the overall investor sentiment regarding ImmuCell suggests that many traders are impartial. The current market sentiment, together with ImmuCell's historical and current headlines, can help investors time the market. In addition, many technical investors use ImmuCell stock news signals to limit their universe of possible portfolio assets.
  
ImmuCell Co. was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 11,700 shares, a growth of 37.6 percent from the September 15th total of 8,500 shares. Approximately 0.3 percent of the companys shares are sold short. Based

Read at thelincolnianonline.com
news
  

ImmuCell Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards ImmuCell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

ImmuCell Fundamental Analysis

We analyze ImmuCell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmuCell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmuCell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Profit Margin

Profit Margin Comparative Analysis

ImmuCell is currently under evaluation in profit margin category among its peers. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

ImmuCell Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ImmuCell stock to make a market-neutral strategy. Peer analysis of ImmuCell could also be used in its relative valuation, which is a method of valuing ImmuCell by comparing valuation metrics with similar companies.

Peers

ImmuCell Related Equities

FENCFennec Pharmaceuticals   12.71   
0%
76.0%
ONTTFOxford Nanopore   12.03   
0%
72.0%
LIPOLipella Pharmaceuticals   8.68   
0%
52.0%
HCWBHCW Biologics   8.45   
0%
50.0%
CVKDCadrenal Therapeutics,   7.00   
0%
41.0%
PTIXProtagenic Therapeutics   6.56   
0%
39.0%
MNOVMediciNova   6.50   
0%
38.0%
TPSTTempest Therapeutics   2.25   
0%
13.0%
RZLTRezolute   1.03   
0%
6.0%
TRGNFTransgene   0.00   
0%
0%
XOMAOXOMA   0.32   
1.0%
0%
ACOGFAlpha Cognition   0.52   
3.0%
0%
ELYMEliem Therapeutics   2.60   
15.0%
0%
ANEBAnebulo Pharmaceuticals   2.67   
16.0%
0%
LCTXLineage Cell   16.67   
100.0%
0%

Complementary Tools for ImmuCell Stock analysis

When running ImmuCell's price analysis, check to measure ImmuCell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuCell is operating at the current time. Most of ImmuCell's value examination focuses on studying past and present price action to predict the probability of ImmuCell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuCell's price. Additionally, you may evaluate how the addition of ImmuCell to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios